Publications

2022

Laccetti, A. et al. Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer: Results From the First-in-Human Dose Escalation Phase 1a Study. Prostate Cancer Foundation (PCF) 2022 Scientific Retreat.
Read More > PCF 2022 Poster Presentation
Hong, NH. et al. Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models. 2022 American Association for Cancer Research (AACR) Annual Meeting.
Read More > AACR 2022 Poster Presentation

Hong, NH. et al. Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor. 2021 Prostate Cancer Foundation (PCF) Annual Scientific Retreat.
Read More > PCF 2021 Poster Presentation
Hong, NH. et al. Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor. 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. (Abstract: P192).
Read More > AACR-NCI-EORTC 2021 Poster Presentation
Hong, NH. et al. Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor. 2021 AACR. (Abstract Number: 1209).
Read More > AACR 2021 Poster Presentation